AstraZeneca won't advertise its new indication

Share this article:
AstraZeneca will not run TV or print ads for its recently approved pediatric indication on Nexium. The firm told the Delaware News Journal it would instead partner with patient advocacy groups to inform doctors that the drug is now approved as an acid reflux treatment for children ages 12–17.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.